In a novel feat, British researchers will test around 14 lung cancer drugs from AstraZeneca and Pfizer simultaneously within one trial.
The idea is to find out medicines that can fight advanced lung cancer according to the genes of the patient. The $42-million project is a partnership between Cancer Research UK and pharmaceutical companies AstraZeneca and Pfizer and the NHS which will allow to use 14 medications which target very specific and often rare genetic mutations.
Cancer or Clearing Wrinkles: Anti-Ageing Creams Give You Both
Anti-ageing creams, which promise to smooth away the fine lines of maturity, could lead to cancer by stripping the skin of its protective top layer, warn experts.
Advertisement
Dr Harpal Kumar, Cancer Research UK's chief executive, says, "This is a very important step forward in the fight against cancer. This partnership is exciting because we're trying to achieve something that none of us could manage alone - targeting treatments towards the patients who we know are the most likely to benefit."
On the basis of the genetics of each lung tumour, researchers will select a small group of patients who are more likely to gain from a certain drug.
![Scientists Identify Protein That Plays A Vital Role In Lung Cancer In Non-Smokers]( "Scientists Identify Protein That Plays A Vital Role In Lung Cancer In Non-Smokers")
Ohio State University Comprehensive Cancer Center and at the National Cancer Institute scientists have identified a protein that appears to play a vital role in lung cancer in non-smokers.
Medicines that work in the small groups of patients will be taken up for larger trials involving more patients with the same kind of genetic changes.
For any particular cancer, single gene mutation can be extremely rare, probably affecting as few as 1 or 2 per cent of patients, thus, studying one drug at a time is extremely difficult.
Source: Medindia
Scientists Identify Protein That Plays A Vital Role In Lung Cancer In Non-Smokers
Ohio State University Comprehensive Cancer Center and at the National Cancer Institute scientists have identified a protein that appears to play a vital role in lung cancer in non-smokers.
Advertisement
Medicines that work in the small groups of patients will be taken up for larger trials involving more patients with the same kind of genetic changes.
For any particular cancer, single gene mutation can be extremely rare, probably affecting as few as 1 or 2 per cent of patients, thus, studying one drug at a time is extremely difficult.
Source: Medindia
One in Three Cancer Trials Use Flawed Methodology: Research
More than one in three group-based cancer trials used a flaw statistical methodology to study the effects of an intervention, according to a study published Tuesday that reviewed 75 articles.
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Research News
A new study explored the link between T immune cells in ill patients and mortality risk.
Limb savage procedure benefits patients with severe vascular disease who are at risk for amputation of their limbs.
Does omega-3 help Alzheimer's patients? A new form of omega-3 helped restore specific markers of eye health in mice bred with aspects of early-onset Alzheimer's disease.
Drugs used to inhibit the physiological responses for allergic reactions lessen osteoarthritis risk, revealed research.
The International Space Station will be used to carry out experiments seeking to improve understanding of incurable child brain tumors and the muscle aging process.